Welcome to our dedicated page for Mirion Technologies news (Ticker: MIR), a resource for investors and traders seeking the latest updates and insights on Mirion Technologies stock.
Mirion Technologies Inc (MIR) delivers critical radiation safety solutions for nuclear energy, healthcare, and global security markets. This news hub provides investors and industry professionals with essential updates on the company developments shaping radiation detection technologies.
Access timely reports covering earnings announcements, product innovations, strategic partnerships, and regulatory milestones. Our curated collection features press releases and analysis on Mirion's Nuclear & Safety segment advancements and Medical division breakthroughs in cancer treatment safety.
Key updates include radiation monitoring system launches, international expansion efforts, and R&D initiatives addressing emerging nuclear safety challenges. Bookmark this page for structured access to operational updates from Mirion's global facilities and executive leadership commentary.
For stakeholders tracking radiation protection technologies, this resource offers comprehensive monitoring of Mirion's progress in dosimetry systems, environmental monitoring solutions, and medical radiation processing advancements. Return regularly for verified updates maintaining compliance with financial disclosure standards.
Varian, a Siemens Healthineers company, and Sun Nuclear, a Mirion Medical company (NYSE: MIR), have announced an alliance to expand Varian's quality assurance (QA) offerings for radiotherapy solutions. Under the agreement, Varian will sell Sun Nuclear's SunCHECK® quality management platform across its sales channels, broadening QA support for its treatment delivery solutions.
Sun Nuclear, a market leader in radiation oncology quality management, has solutions used in over 6,000 cancer treatment facilities. The alliance aims to enhance clinical workflows, improve treatment outcomes, and ease radiation therapy technology adoption. Varian will continue to support existing QA customers while expanding its comprehensive QA offerings.
As part of the agreement, Varian and Sun Nuclear will also enhance the integration of QA software for future radiotherapy offerings, reinforcing Varian's commitment to excellence in patient care and safety.
Mirion (NYSE: MIR) reported Q2 2024 financial results with revenues increasing 5.0% to $207.1 million. The company saw a net loss of $12.0 million, an improvement from $28.4 million loss in Q2 2023. Adjusted EBITDA rose 10.2% to $48.8 million, with margin expanding to 23.6%. Mirion raised its full-year adjusted EBITDA guidance to $195-$205 million while reiterating 5-7% revenue growth and $0.37-$0.42 adjusted EPS guidance. The company also announced a strategic nuclear new build partnership with EDF, strengthening its position in the nuclear market.
Mirion Technologies (NYSE: MIR) has announced its schedule for the release of second quarter 2024 financial results. The company will disclose its earnings after market close on Thursday, August 1, 2024, followed by a conference call on Friday, August 2, 2024, at 11:00 am ET to discuss the results.
Investors and analysts can participate in the call by dialing 1-877-407-9208 (US) or 1-201-493-6784 (international). A live webcast will be available on the company's investor relations website. For those unable to attend, a telephonic replay will be accessible until August 16, 2024, using the access code 13747541.
Mirion (NYSE: MIR) has announced a change in timing for its management team's presentation at the Jefferies’ 2024 Global Healthcare Conference. The presentation will now start at 3:30 PM ET on Thursday, June 6, 2024. The event will be webcast live on Mirion's investor relations website under the 'Events and Presentations' section. An archived version of the webcast will be accessible within twelve hours after the event concludes.
Mirion (NYSE: MIR), a global radiation detection and monitoring solutions provider, announced the completion of the redemption of its outstanding publicly traded warrants. As of May 20, 2024, Mirion redeemed the warrants at $0.10 each. Of the 18,749,779 warrants, 2,131 were exercised for cash, and 18,074,285 were exercised on a cashless basis, resulting in a total of 3,978,418 new common shares issued. The remaining 673,363 unexercised warrants were redeemed for $67,336.30. The public warrants ceased trading on the NYSE before the market opened on May 20, 2024. The private placement warrants remain unaffected and continue to be outstanding. The common shares continue to trade under the symbol 'MIR'. Additional details are available on Mirion’s Investor Relations website.
Mirion (NYSE: MIR) announced that its CEO Thomas Logan and CFO Brian Schopfer will present at Jefferies’ 2024 Global Healthcare Conference in New York, NY. The presentation is scheduled for June 6, 2024, at 4:00 PM ET.
The event will be webcast live and accessible via Mirion's investor relations website, with an archived version available within twelve hours post-event.
Mirion announced its first quarter 2024 financial results, with revenues increasing by 5.8% to $192.6 million and a net loss of $26.5 million. Adjusted EBITDA rose to $39.5 million, and the company reaffirmed its full year guidance, expecting revenue growth of 5% to 7% and adjusted EPS of $0.37-$0.42.
FAQ
What is the current stock price of Mirion Technologies (MIR)?
What is the market cap of Mirion Technologies (MIR)?
